Leung David Ka-Wai, Chiu Peter Ka-Fung, Ng Chi-Fai, Teoh Jeremy Yuen-Chun
S. H. Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Biomedicines. 2021 Mar 27;9(4):339. doi: 10.3390/biomedicines9040339.
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant prostate cancer. Three novel hormonal agents showed survival benefits in non-metastatic patients. As for metastatic disease, there was an even wider range of management options being investigated. This review summarized advances in the management of castration-resistant prostate cancer (CRPC) including emerging data on novel imaging techniques and treatment strategies.
对于绝大多数晚期前列腺癌患者而言，去势抵抗的发展是一条不可避免的路径。近来，在去势抵抗性前列腺癌的认识和治疗选择方面取得了重大突破。三种新型激素药物在非转移性患者中显示出生存获益。至于转移性疾病，正在研究更广泛的治疗选择。本综述总结了去势抵抗性前列腺癌（CRPC）治疗方面的进展，包括新型成像技术和治疗策略的新数据。
